ALKS
Alkermes Plc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.
Market Cap: 2.19 Billion
Primary Exchange: NASDAQ
Website: http://www.alkermes.com
Shares Outstanding: 158 Million
Float: 156 Million
Dividend: (%)
Beta: 0.846470401728837
Sector: Health Technology
Industry: Biotechnology
Ethical Flags
Longest drawdown: 1602 trading days
From: 2015-12-28 To: 2020-04-01
Lowest Point:
Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma
via: PR Newswire at 2019-06-12 03:00:00:000
-- Initiation of Monotherapy Efficacy Evaluation Follows Selection of Recommended Phase 2 Dose in Dose-Escalation Stage -- -- Proof-of-Mechanism Demonstrated by Desired Expansion of Tumor-Killing Immune Cells While Avoiding Activation of Immunosuppressive Cells -- DUBLIN , June 12… read more...
Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma
via: PR Newswire at 2019-06-12 03:00:00:000
-- Initiation of Monotherapy Efficacy Evaluation Follows Selection of Recommended Phase 2 Dose in Dose-Escalation Stage -- -- Proof-of-Mechanism Demonstrated by Desired Expansion of Tumor-Killing Immune Cells While Avoiding Activation of Immunosuppressive Cells -- DUBLIN , June 12… read more...
FDA Ad Com tomorrow on utility of higher-dose opioids
via: SeekingAlpha at 2019-06-10 13:06:51:000
The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will jointly mee t tomorrow and Wednesday, June 11 & 12, to seek public input on the clinical utility and safety concerns associated with higher range opioid an… read more...
FDA Ad Com tomorrow on utility of higher-dose opioids
via: SeekingAlpha at 2019-06-10 13:06:51:000
The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will jointly mee t tomorrow and Wednesday, June 11 & 12, to seek public input on the clinical utility and safety concerns associated with higher range opioid an… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|